NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

000067-C

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 2 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Neonates

Keywords

CD-19 expressing tumor;
CD-22 Expressing Tumor;
Adaptive Immunotherapy;
Caregivers;
Natural History

Recruitment Keyword(s)

None

Condition(s)

Acute Lymphoid Leukemia;
B-Cell Leukemia;
Lymphoma, Non-Hodgkin;
Neoplasms;
B-Cell Lymphoma

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

Background:

Doctors want to learn more about what it is like to receive CAR T-cell cancer therapy. Most of what they know comes from what a person s doctors or nurses report about their symptoms. Researchers think that this may not fully describe what this treatment is like for people and their families. They want to help people and their families know what to expect when they go through treatment with CAR T-cells.

Objective:

To better understand what it is like for young people to be treated with CAR T-cell therapies.

Eligibility:

People ages 8 to 25 or caregivers of a child aged 2 to 25 who will be treated with CAR T-cell therapy at the National Cancer Institute - Pediatric Oncology Branch.

Design:

Participants will be screened with a review of their medical records.

Participants will be enrolled on the CAR T PROs study. This will include up to 10 surveys. The surveys will take 10 to 30 minutes each. It will also include one interview. The interview will take about 30 to 60 minutes. Surveys can be done on paper or an electronic version using a secure survey tool.

For caregivers, surveys will be completed by one caregiver at each time point. The

interview is open to both caregivers, if this applies.

During the study, participants might have to go to the hospital for side effects of the CAR T-cell therapy. If this happens, they may be asked to complete another survey at that time.

Interviews with participants will be audiotaped or digitally recorded.

Participants will be in the study for one year.

--Back to Top--

Eligibility

Eligibility:

- Patient Participants ages 2-25 years old

-- Any cancer diagnosis

-- Scheduled to receive CAR T cell therapy

- Caregiver Participants

-- Primary caregiver of a patient 2 to 25 years who is scheduled to receive CAR T cell therapy

- Speak and read English or Spanish


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Sara K. Silbert, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 1-3750
10 CENTER DR
BETHESDA MD 20892
(240) 760-6560
sara.silbert@nih.gov

NCI Pediatric Leukemia, Lymphoma Transpl
National Cancer Institute (NCI)

(240) 760-6970
ncilltct@mail.nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937
ncimo_referrals@mail.nih.gov

--Back to Top--

NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

000067-C

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 2 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Neonates

Keywords

CD-19 expressing tumor;
CD-22 Expressing Tumor;
Adaptive Immunotherapy;
Caregivers;
Natural History

Recruitment Keyword(s)

None

Condition(s)

Acute Lymphoid Leukemia;
B-Cell Leukemia;
Lymphoma, Non-Hodgkin;
Neoplasms;
B-Cell Lymphoma

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

Background:

Doctors want to learn more about what it is like to receive CAR T-cell cancer therapy. Most of what they know comes from what a person s doctors or nurses report about their symptoms. Researchers think that this may not fully describe what this treatment is like for people and their families. They want to help people and their families know what to expect when they go through treatment with CAR T-cells.

Objective:

To better understand what it is like for young people to be treated with CAR T-cell therapies.

Eligibility:

People ages 8 to 25 or caregivers of a child aged 2 to 25 who will be treated with CAR T-cell therapy at the National Cancer Institute - Pediatric Oncology Branch.

Design:

Participants will be screened with a review of their medical records.

Participants will be enrolled on the CAR T PROs study. This will include up to 10 surveys. The surveys will take 10 to 30 minutes each. It will also include one interview. The interview will take about 30 to 60 minutes. Surveys can be done on paper or an electronic version using a secure survey tool.

For caregivers, surveys will be completed by one caregiver at each time point. The

interview is open to both caregivers, if this applies.

During the study, participants might have to go to the hospital for side effects of the CAR T-cell therapy. If this happens, they may be asked to complete another survey at that time.

Interviews with participants will be audiotaped or digitally recorded.

Participants will be in the study for one year.

--Back to Top--

Eligibility

Eligibility:

- Patient Participants ages 2-25 years old

-- Any cancer diagnosis

-- Scheduled to receive CAR T cell therapy

- Caregiver Participants

-- Primary caregiver of a patient 2 to 25 years who is scheduled to receive CAR T cell therapy

- Speak and read English or Spanish


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Sara K. Silbert, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 1-3750
10 CENTER DR
BETHESDA MD 20892
(240) 760-6560
sara.silbert@nih.gov

NCI Pediatric Leukemia, Lymphoma Transpl
National Cancer Institute (NCI)

(240) 760-6970
ncilltct@mail.nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937
ncimo_referrals@mail.nih.gov

--Back to Top--